oxybutynin has been researched along with Abnormal Movements in 2 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Blonanserin is a second-generation antipsychotic for the treatment of schizophrenia." | 9.51 | Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study. ( Kuramitsu, A; Ohi, K; Shioiri, T; Sugiyama, S; Takai, K, 2022) |
| "Blonanserin is a second-generation antipsychotic for the treatment of schizophrenia." | 5.51 | Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study. ( Kuramitsu, A; Ohi, K; Shioiri, T; Sugiyama, S; Takai, K, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohi, K | 1 |
| Takai, K | 1 |
| Kuramitsu, A | 1 |
| Sugiyama, S | 1 |
| Shioiri, T | 1 |
| Diaz, MCB | 1 |
| Rosales, RL | 1 |
1 trial available for oxybutynin and Abnormal Movements
| Article | Year |
|---|---|
Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, | 2022 |
1 other study available for oxybutynin and Abnormal Movements
| Article | Year |
|---|---|
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dyskinesias; Electroencephalography | 2015 |